

## Supplementary Materials for

### **Gut-Liver physiomimetics reveal paradoxical modulation of IBD-related inflammation by short-chain fatty acids**


Martin Trapecar<sup>1</sup>, Catherine Communal<sup>1</sup>, Jason Velazquez<sup>1</sup>, Christian Alexander Maass<sup>1,2</sup>, Yu-Ja Huang<sup>1</sup>, Kirsten Schneider<sup>1</sup>, Charles W. Wright<sup>1</sup>, Vincent Butty<sup>1,3</sup>, George Eng<sup>4,5</sup>, Omer Yilmaz<sup>4</sup>, David Trumper<sup>6,7</sup>, Linda G. Griffith<sup>1,6,8\*</sup>

Correspondence to: [griff@mit.edu](mailto:griff@mit.edu)

#### **This file includes:**


Figures S1 to S7  
Table S1

## Supplementary figures






**Fig.S1**

**Gut donor of each MPS can be predicted with 100% accuracy by random forest analysis based on cytokines released during gut MPS-Treg/Th17 interaction.** (A) Representative values of individual cytokines measured in media of UC and healthy epithelial monolayers, UC and healthy gut MPS and MPS co-cultures with Treg/Th17 cells (B) Concentration of TGF- $\beta$ 1, TGF- $\beta$ 2 and IL-17 in basal media of UC and healthy gut MPS during interaction with Treg/Th17 cells (A-B) \*FDR<0.05; \*\*FDR<0.01; \*\*\*FDR<0.001; \*\*\*\*FDR<0.0001. (C) List of top 10 differential gene expression pathway enrichments, ranked based on combined z and p score, by Wikipathway analysis of UC gut MPS over healthy control (D) Random forest analysis of cytokines shown under (A) during UC and healthy MPS interaction with Treg/Th17 cells. Confusion matrix indicates prediction accuracy. Each condition was tested in separate experiments with 3-5 biological replicates.






**Fig.S2**  
**Platform operation, circulating CD4 T cell viability and schematic models to calculate SCFA metabolism and distribution.** (A) Operational parameters of the 3XGL platform with the gut and liver MPSs. (B) Schematic overview of the utilized compartmental model to describe SCFA distribution, metabolism in the gut MPS;  $P_{gut}$  = permeability,  $A_{gut}$  = surface area of transwell,  $CL$  = metabolism. (C) Schematic overview of the four-compartmental model consisting of a gut, liver and mixing chamber MPS. In addition to gut-specific SCFA permeability and consumption, liver metabolism was implemented to describe the distribution.



**Fig.S3**




**SCFA distribution and its effect on global gene expression and functional parameters of gut and liver function during gut-liver interaction with or without SCFA and Treg/Th17 cells.** (A) Apical concentrations of acetate, propionate and butyrate in UC gut MPS and their bioavailable concentrations in basal common medium during 96h of interaction. Far right: hepatic clearance of bioavailable SCFA. (B) Complete linkage and cluster heatmap of genes expressed by all tissues collected during the study. (C) Representative brightfield images of epithelial monolayers at day 0 of interaction, prior to basolateral seeding of MACs/DCs, and that of gut MPS monolayers with underlying MACs/DCs at day 2 and day 4 of interaction (D) TEER of UC gut MPS used in the interaction studies as well as the control. D0: at the beginning of the interaction, D2: TEER of the control gut MPS in isolation, D4: end of the interaction. \*\*\*\*FDR<0.0001. (E) Albumin concentrations produced by the liver MPS before, during and at the end of interaction measured in common medium.



Seed state: 3; Number of trees:100



**Fig.S4**

**Effect of SCFA on cytokine/chemokine expression during gut-liver interaction in the absence of Treg//Th17 cells.** (A) log<sub>2</sub> Fold changes of individual multiplexed cytokines/chemokines measured in the common medium of the gut-liver and gut-liver-SCFA interactions. p values indicate 2-Way ANOVA difference between SCFA treated and non-treated groups. (B) Concentrations of cytokines/chemokines identified by random forest analysis to be most predictive of condition. \*FDR<0.05; \*\*FDR<0.01; \*\*\*FDR<0.001; \*\*\*\*FDR<0.0001. (C) Random forest analysis of all cytokines/chemokines measured. Top left: Number of trees required to complete confusion matrix. Bottom left: Confusion matrix indicating prediction accuracy. Right: Importance matrix of most predictive parameters.

**A****B****C****Fig.S5**


**SCFA and systemic inflammation affect glucose metabolism and production of ketone bodies.** (A-C) Scaled intensities of glucose, pyruvate and lactate at days 2 and 4 (A), aconitate (B), and BHBA (C) at day 2 for interactions among all 4 experimental conditions, MPS controls in isolation and common media. \*p < 0.05; \*\*p < 0.01.





**Fig.S6**

**Effect of SCFA on cytokine/chemokine expression during gut-liver interaction in the presence of Treg//Th17 cells** (A) log<sub>2</sub> Fold changes of individual multiplexed cytokines/chemokines measured in the common medium of the gut-liver-Treg/Th17 and gut-liver-Treg/Th17-SCFA interactions. p values indicate 2-Way ANOVA difference between SCFA treated and non-treated groups. (B) Concentrations of cytokines/chemokines identified by random forest analysis to be most predictive of condition. \*FDR<0.05; \*\*FDR<0.01; \*\*\*FDR<0.001; \*\*\*\*FDR<0.0001. (C) Random forest analysis of all cytokines/chemokines measured. Top left: Number of trees required to complete confusion matrix. Bottom left: Confusion matrix indicating prediction accuracy. Right: Importance matrix of most predictive parameters.



**Fig.S7**  
**Effect of SCFA on inflammation related metabolic products during gut-liver interaction (A,B)** Scaled intensities of tryptophan, kynurenine and kynurenate (A) as well as quinolinolate, nicotinamide and nicotinamide riboside (B) at days 2 and 4 for interactions among all 4 conditions, MPS controls in isolation and common media. \* $p < 0.05$ ; \*\* $p < 0.01$ .

## Supplementary tables

Table S1. Overview of model parameters

Parameter name	Acronym	Value	Unit
Permeability	$P_{\text{gut}}$	Estimated	cm/min
Surface area	$A_{\text{gut}}$	0.33	cm <sup>2</sup>
Metabolism gut	$Cl_{\text{gut}}$	Estimated	ml/min
Metabolism liver	$Cl_{\text{liv}}$	Estimated	ml/min
Media volume gut	$V_{\text{apical}}$	0.5	ml
	$V_{\text{basal}}$	1.5	ml
Media volume liver	$V_{\text{liv}}$	1.6	ml
Media volume mixer	$V_{\text{mix}}$	2.5	ml
Systemic flow rate	$Q_{\text{mix}}$	30	ml/day
Flow partitioning gut	$Q_{\text{gut}}$	$0.75 \cdot Q_{\text{mix}}$	ml/day
Flow partitioning liver	$Q_{\text{hep}}$	$0.25 \cdot Q_{\text{mix}}$	ml/day